MLYS Mineralys Therapeutics, Inc.: institutional ownership and insider trading
234 funds reported holding $2.89B of Mineralys Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $128M, with 31 new positions and 23 funds selling out; over the last 12 months insiders bought $8.76M and sold $88.0M on the open market.
MLYS revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$241M, EPS -2.85
- Quarter ended Mar 31, 2026: revenue n/a, net income −$39.3M, EPS -0.47
- Quarter ended Dec 31, 2025: revenue n/a, net income −$32.2M, EPS -0.32
- Quarter ended Sep 30, 2025: revenue n/a, net income −$36.9M, EPS -0.52
Famous investors holding MLYS
- Izzy Englander (Millennium Management): $33.8M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $10.2M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $16.1M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $9.52M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $4.37M, 0.0% of the portfolio
Largest institutional holders of MLYS
- Catalys Pacific, LLC — $213M
- RA CAPITAL MANAGEMENT, L.P. — $208M
- BlackRock, Inc. (BLK) — $159M
- Samsara BioCapital, LLC — $158M
- FMR LLC — $122M
- VANGUARD GROUP INC — $122M
- STATE STREET CORP (STT, STT-PG) — $112M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $107M
- ARMISTICE CAPITAL, LLC — $74.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $74.4M
Recent MLYS insider trades
- Sep 30, 2026: Congleton Jon sold 75,000 shares ($1.91M)
- Sep 22, 2026: Slingsby Brian Taylor sold 104,320 shares ($3.01M)
- Sep 21, 2026: Warren Eric sold 7,438 shares ($209K)
- Sep 15, 2026: Karydas Daphne sold 3,000 shares ($85.7K)
5%+ owners
- FMR LLC: 5.1% (Schedule 13G/A, filed Aug 6, 2026)